Cargando…
Molecular Diagnosis and Novel Therapies for Neuromuscular Diseases
With the development of novel targeted therapies, including exon skipping/inclusion and gene replacement therapy, the field of neuromuscular diseases has drastically changed in the last several years. Until 2016, there had been no FDA-approved drugs to treat Duchenne muscular dystrophy (DMD), the mo...
Autores principales: | Maruyama, Rika, Yokota, Toshifumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564006/ https://www.ncbi.nlm.nih.gov/pubmed/32947786 http://dx.doi.org/10.3390/jpm10030129 |
Ejemplares similares
-
Editorial: Genome and transcriptome editing to understand and treat neuromuscular diseases
por: Maruyama, Rika, et al.
Publicado: (2023) -
Molecular Diagnosis of Neuromuscular Disease
por: Sertic, Jadranka
Publicado: (2004) -
Skipping Multiple Exons to Treat DMD—Promises and Challenges
por: Aslesh, Tejal, et al.
Publicado: (2018) -
Muscular Dystrophy: Disease Mechanisms and Therapies
por: Pandey, Sachchida Nand, et al.
Publicado: (2015) -
Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy
por: Lee, Joshua J.A., et al.
Publicado: (2018)